RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 194 participants.

Also called NCT07203521

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 194 participants (planned count) (from the registry)
Sponsor
Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd (from the registry)
Registry
  • NCT NCT07203521
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07203521. Randomized; single masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
Condition
Acute Large Hemispheric Infarction Stroke
Condition
Transcranial Bone Marrow Injection
Condition
RK-4
Condition
Acute Ischemic Stroke
Intervention (Drug)
RK-4 injection
Intervention (Other)
conventional treatment
Lead sponsor
Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd (class: other government)

Record details

Record id
cardio:ct-nct07203521
Content hash
78b7f1e1ca7e7fa34dd1da453fdb8134f721eab1c363119b564847e956b46d24